CytoSorbents Corp. (NSDQ:CTSO) shares jumped 9% to $5.35 apiece today after the company reported that it landed a permanent reimbursement procedure code for its CytoSorb therapy in Germany.
The Monmouth Junction, N.J.-based company developed its blood purification therapy to treat inflammation in critically-ill patients and for use during cardiac surgery. CytoSorb is an extracorporeal cytokine filter, made up of biocompatible, porous polymer beads that use pore capture and surface adsorption to remove toxic substances from the blood and other bodily fluids.
Get the full story at our sister site, Medical Design & Outsourcing.
The post CytoSorbents gains on German reimbursement win appeared first on MassDevice.
from MassDevice http://ift.tt/2gUExIY
Cap comentari:
Publica un comentari a l'entrada